Drugs / RO6811135
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01789788 | Mar → Sep 2013 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01676584 | Sep → Dec 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01951183 | Dec 2013 | type 2 diabetes mellitus | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01802853 Comparator | May → Jun 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO6811135 | “Drug: RO6811135” NCT01951183 ↗ |
| Route | Subcutaneous | “single ascending doses sc” NCT01676584 ↗ |